Successful development of anti-tumor catalyst of humanwell Pharmaceutical Research Institute

The project "preparation of a copper carbene catalyst and its application in the research and development of bortezomib" completed by humanwell Pharmaceutical Research Institute has recently been identified by the technical achievements of Wuhan Science and Technology Bureau The catalyst is successfully developed by humanwell pharmaceutical in the world, which can realize mass production and low cost It is reported that the chiral selectivity of the catalyst is as high as 99.5% and the yield is as high as 90% The reaction conditions are easy to operate, the reaction at room temperature does not need strict oxygen free The application of the catalyst is the key of drug synthesis technology It can not only be used in the key control steps of the preparation process of bortezomib API, but also play an important role in the synthesis process of other drugs Dr Xu Yong, executive vice president of humanwell Pharmaceutical Research Institute, said: "from the perspective of treatment cost, the anti-tumor drug produced without the catalyst needs at least 10000 yuan for one injection, and 40000 yuan for a single course of treatment The application of the technology can greatly reduce the production cost of the drug synthesis process and reduce the economic burden of patients This project has been basically completed, and the products will be applied for clinical application with three kinds of generic pharmaceutical qualifications by the end of this year " In addition, the preparation method of eletroptan will be used for the treatment of migraine with or without aura in adults Recently, it has also obtained the patent license for invention As a major national new drug development undertaking unit, humanwell pharmaceutical currently has 10 leading class a new drugs in the clinical stage Humanwell pharmaceutical is mainly engaged in the pharmaceutical industry, and its market segments include anesthetics and analgesics, birth control drugs, blood products, Uyghur ethnic medicine, etc currently, anticancer drugs are not the main research and development fields of the company